Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

For Second Kidney Xenotransplant Patient Discharged, Immunosuppression Is Key

Key Takeaway: The article discusses the successful discharge of a second patient who received a kidney xenotransplant. It emphasizes the importance of immunosuppression in ensuring the patient's recovery. This achievement marks a significant milestone in the field of organ transplantation, showcasing advancements in medical technology.
Price reaction · baseline $4.5 (2025-02-12 close) · hit after-hours · 2 other ELDN headline(s) in the window, move may be shared
day 0 close
-0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful discharge of a second kidney xenotransplant patient.
  • Immunosuppression plays a crucial role in the patient's recovery.
  • Highlights advancements in organ transplantation technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is kidney xenotransplantation?

Kidney xenotransplantation involves transplanting a kidney from one species to another, often from animals to humans.

Why is immunosuppression important in xenotransplantation?

Immunosuppression is crucial to prevent the recipient's immune system from rejecting the transplanted organ.

How many patients have been discharged after kidney xenotransplant?

This article mentions the successful discharge of a second patient after receiving a kidney xenotransplant.

What advancements are highlighted in this article?

The article highlights advancements in organ transplantation technology, particularly in xenotransplantation.

Last updated: Feb 12, 2025